Elanco Animal Health Inc

Elanco Animal Health Incorporated develops, manufactures, and markets products to prevent and treat disease in pets and farm animals. Operating as a single segment within the animal health industry, the company provides treatments primarily for dogs, cats, cattle, poultry, swine, and sheep. Its product line encompasses parasiticides, dermatology treatments, vaccines, pain management therapeutics, medicated feed additives, injectable antibiotics, and enzymes. Elanco distributes its pet care offerings to third-party distributors, retailers, and veterinary clinics, while its farm animal products are supplied to commercial distributors and livestock producers.

The company sells its portfolio across more than 90 countries, with the United States representing its largest market alongside key international markets in Brazil, the United Kingdom, and China. Global commercial operations are supported by 16 manufacturing facilities situated across eight countries, as well as an extensive network of contract manufacturing organizations and international research and development sites. Elanco maintains its research and development headquarters in Indianapolis, Indiana.

Summary of the business section of Elanco Animal Health's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we employed approximately 9,400 full time employees and approximately 500 fixed-duration employees, which are individuals hired for a pre-defined length of time (typically one to four years).”